If you are also having GI side effects, those can also contribute to fatigue, in addition to hypoglycemia or eating less calories/carbs than before.
@StonePny just mentioned naltrexone in another thread. But you may have already tried it, so it may not help much if you lower your tirz dose. I have already added it for my next order from
India to try with other things to augment my tirz.
Have you tried other GLPs? According to Google Gemini, tirz and sema may be the most likely to cause hypo:
Medication Class Mechanism of Action (Glucose & Appetite) Likelihood of Hypoglycemia (as monotherapy) Impact on Food Noise/Fullness/Binge Eating Notes Retatrutide Investigational GLP-1/GIP/Glucagon RA Agonist of GLP-1, GIP (satiety signals), and glucagon (potential counter to hypoglycemia) Potentially Very Low Significant potential for reduced food noise, increased fullness, and decreased binge eating due to GLP-1 and GIP agonism. Glucagon receptor activity may help counter hypoglycemia. Still under investigation, more data needed on all effects. Survodutide Investigational GLP-1/Glucagon RA Agonist of GLP-1 (satiety signals) and glucagon (potential counter to hypoglycemia) Potentially Very Low Likely to reduce food noise and increase fullness due to GLP-1 agonism, potentially aiding in preventing binge eating. Glucagon receptor activity may help counter hypoglycemia. Still under investigation, more data needed on all effects. Semaglutide GLP-1 Receptor Agonist Enhances glucose-dependent insulin secretion, suppresses postprandial glucagon secretion, slows gastric emptying (increasing fullness) Low to Moderate Known to reduce food noise, increase feelings of fullness, and can be effective in reducing binge eating tendencies for some individuals. Risk of hypoglycemia is higher when used with insulin or sulfonylureas. Gastrointestinal side effects can occur. Tirzepatide GIP and GLP-1 Receptor Agonist Enhances glucose-dependent insulin secretion, suppresses glucagon secretion, likely has significant effects on satiety pathways through GIP and GLP-1 agonism. Low to Moderate Demonstrates strong effects on reducing food noise, promoting fullness, and aiding in weight loss, suggesting a potential to reduce binge eating. Risk of hypoglycemia is higher when used with insulin or sulfonylureas. Gastrointestinal side effects can occur.
Also from Gemini: "While GLP-1 is well-known for slowing gastric emptying and promoting satiety, GIP can complement these actions through its own pathways in the brain and potentially by influencing energy balance and fat metabolism. This combined action may lead to a more potent reduction in food noise compared to a GLP-1 agonist alone."
Instead of switching to reta, some of us will add survo to tirz.